(Reuters) – Belgian biotech group Ablynx on Wednesday said it had tripled its research deal with U.S. drugmaker Merck & Co leading to potential milestone payments of about 4 billion euros ($4.38 billion).
Large pharmaceutical groups such as Merck & Co often team up with smaller companies like Ablynx to develop new treatments. A so-called milestone payment is due whenever a programme passes a certain trial phase or clinical tests are successful.
Ablynx, which produces so-called nanobody medicines derived from llama antibodies, said it had expanded its research agreement with Merck & Co by 12 programmes for which it could receive up to 340 million euros each if successful.
The group added it would get a 13 million euro upfront payment for signing the deal expansion. The initial agreement with the U.S. group, signed in February 2014, contained payments of up to 1.7 billion euros. ($1 = 0.9142 euros) (Reporting by Robert-Jan Bartunek; Editing by Anand Basu)
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.